Zobrazeno 1 - 10
of 55
pro vyhledávání: '"James K. McCloskey"'
Autor:
Andrew Ip, Alexandra Della Pia, Gee Youn (Geeny) Kim, Jason Lofters, James Behrmann, Dylon Patel, Simone Kats, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Andrew L. Pecora, Andre H. Goy, Jamie Koprivnikar, James K. McCloskey, Maher Albitar
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionCytogenetic analysis is important for stratifying patients with various neoplasms. We explored the use of targeted next generation sequencing (NGS) in detecting chromosomal structural abnormalities or copy number variations (CNVs) in pati
Externí odkaz:
https://doaj.org/article/841f74756f494596ab6c774a50e1ff13
Autor:
Michael Robert Savona, James K Mccloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Aref Al-Kali, H. Joachim Deeg, Prapti A. Patel, Mitchell Sabloff, Mary-Margaret Keating, Nancy Y Zhu, Nashat Gabrail, Salman Fazal, Joseph J. Maly, Olatoyosi Odenike, Hagop Kantarjian, Amy Dezern, Casey L Oconnell, Gail Roboz, Lambert Busque, Rena Buckstein, Harshad Amin, Jasleen K Randhawa, Brian Leber, Kim-Hien Dao, Winny Chan, Aram Oganesian, Yuri Sano, Beloo Mirakhur, Harold Keer, Guillermo Garcia-Manero
Publikováno v:
HemaSphere, Vol 7, p e1342620 (2023)
Externí odkaz:
https://doaj.org/article/d714ae49ea90429fa3bcf0183321b904
Autor:
Michael R. Savona, James K McCloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Aref Al-Kali, Joachim Deeg, Prapti Patel, Mitchell Sabloff, Mary-Margaret Keating, Kim-Hien Dao, Nancy Zhu, Nashat Y. Gabrail, Salman Fazal, Joseph J. Maly, Olatoyosi Odenike, Hagop Kantarjian, Amy E. DeZern, Casey L. O'Connell, Gail J. Roboz, Lambert Busque, Rena Buckstein, Harshad Amin, Jasleen K. Randhawa, Brian Leber, Aram Oganesian, Winny Chan, Yong Hao, Mohammad Azab, Guillermo Garcia-Manero
Publikováno v:
Blood. 140:2066-2069
Autor:
Aaron D Goldberg, Mikhail Roshal, Andriy Derkach, Saar Gill, Eric Padron, Brian Ball, Christopher Famulare, Eytan M. Stein, David A. Sallman, Benjamin M Manning, James K. McCloskey, Jamie Koprivnikar, Thomas Prebet, Martin S. Tallman, Rami S. Komrokji, Rebecca Testi, Najla Al Ali
Publikováno v:
Blood Adv
Key Points Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant. Allogeneic stem cell transplantation after treatment with venetoclax in combination with
Autor:
Bhavana Bhatnagar, Ehab Atallah, Benjamin Tomlinson, Leonard T. Heffner, James K. McCloskey, Yajuan Qin, Karin Havenith, Hagop M. Kantarjian, Xiaoyan Zhang, Wendy Stock, Matthew J. Wieduwilt, Nitin Jain, Jay Feingold, Grace Chao, David Ungar, Amer M. Zeidan
Publikováno v:
Blood Advances. 4:449-457
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge. Loncastuximab tesirine is an antibody-drug conjugate against CD19, an antigen expressed in many B-cell malignancies. This open-label, single-arm
Autor:
Naval Daver, Ellen K. Ritchie, James K. McCloskey, Ramon V. Tiu, Alexander E. Perl, Mark R. Litzow, Mark J. Levis, Terrence Bradley, Qin Qin, Joseph Maly, Bo Tong, Gary J. Schiller, Catherine C. Smith, Jessica K. Altman, Kimberley Dilley, Wan-Jen Hong
Publikováno v:
Blood. 136:20-22
Background: The FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib (Gilt) improves survival compared with standard salvage chemotherapy in relapsed/refractory (R/R) FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML); however, relapses are com
Autor:
James K. McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen Anthony Strickland, Amir Tahmasb Fathi, Harry Paul Erba, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald Cheung, Mark J. Levis
Publikováno v:
Journal of Clinical Oncology. 40:7043-7043
7043 Background: CPX-351 (US: Vyxeos; Europe: Vyxeos liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved for newly diagnosed, therapy-related AML or AML with myelodysplasia-rela
Autor:
Maher Albitar, Hong Zhang, Ahmad Charifa, Andrew Ip, Ivan De Dios, Wanlong Ma, James K. McCloskey, Michele Donato, David Samuel DiCapua Siegel, Stanley E. Waintraub, Martin Gutierrez, Andrew L Pecora, Andre Goy
Publikováno v:
Journal of Clinical Oncology. 40:3048-3048
3048 Background: Expressed RNA can capture mutations, gene fusions, and biomarker profiles. In principle, each abnormal cell has one copy of mutated gene, but numerous copies of mutated RNA. Cell-free RNA (cfRNA) is not used due to the assumption tha
Autor:
Daniel A. Pollyea, Anthony S. Stein, Mikhail Roshal, Michael R. Savona, Olatoyosi Odenike, Courtney D. DiNardo, Hongfang Wang, Eric S. Winer, Richard Stone, Aleksandra Franovic, Alice S. Mims, Gert J. Ossenkoppele, Lei Hua, Hartmut Döhner, Martin S. Tallman, Bin Wu, Amir T. Fathi, Prapti A. Patel, Sung Choe, Frederik Lersch, Salah Nabhan, Caroline Almon, Bob Löwenberg, Keith W. Pratz, Mark G. Frattini, Bin Fan, Eytan M. Stein, Michael Cooper, Christopher S. Seet, Hagop M. Kantarjian, James K. McCloskey
Publikováno v:
Blood, 137(13), 1792-1803. American Society of Hematology
Stein, E M, DiNardo, C D, Fathi, A T, Mims, A S, Pratz, K W, Savona, M R, Stein, A S, Stone, R M, Winer, E S, Seet, C S, Döhner, H, Pollyea, D A, McCloskey, J K, Odenike, O, Löwenberg, B, Ossenkoppele, G J, Patel, P A, Roshal, M, Frattini, M G, Lersch, F, Franovic, A, Nabhan, S, Fan, B, Choe, S, Wang, H, Wu, B, Hua, L, Almon, C, Cooper, M, Kantarjian, H M & Tallman, M S 2021, ' Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study ', Blood, vol. 137, no. 13, pp. 1792-1803 . https://doi.org/10.1182/blood.2020007233
Stein, E M, DiNardo, C D, Fathi, A T, Mims, A S, Pratz, K W, Savona, M R, Stein, A S, Stone, R M, Winer, E S, Seet, C S, Döhner, H, Pollyea, D A, McCloskey, J K, Odenike, O, Löwenberg, B, Ossenkoppele, G J, Patel, P A, Roshal, M, Frattini, M G, Lersch, F, Franovic, A, Nabhan, S, Fan, B, Choe, S, Wang, H, Wu, B, Hua, L, Almon, C, Cooper, M, Kantarjian, H M & Tallman, M S 2021, ' Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study ', Blood, vol. 137, no. 13, pp. 1792-1803 . https://doi.org/10.1182/blood.2020007233
Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their effectiveness as single agents in mIDH1/2 relapsed or refractory acute myeloid leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bfd6cb5b71f55c77b68e682671dc850
https://research.vumc.nl/en/publications/7a79b81d-afa9-4ee7-ba19-81eb8409d123
https://research.vumc.nl/en/publications/7a79b81d-afa9-4ee7-ba19-81eb8409d123
Publikováno v:
Journal of Thrombosis and Thrombolysis. 46:483-487
Direct oral anticoagulants (DOACs) have become an attractive option for the treatment of venous thromboembolism (VTE) in cancer patients. However, their use is currently not recommended as first-line treatment by national guidelines due to limited da